2024-07-09 07:44:38 ET
Summary
- Pfizer's cash flow from operations in 2022 was $29.267 billion, driven by COVID-19 vaccine and Paxlovid sales, but dropped to $8.7 billion in 2023.
- Despite revenue loss from COVID-19 drugs, the Company has a strong drug pipeline and scale advantage over rivals.
- Facing patent expirations and challenges from the US Inflation Reduction Act, PFE focuses on oncology drugs, biologics, and future revenue growth.
Pfizer's ( PFE ) cash flow from operations in 2022, driven by sales of the company's COVID-19 vaccine and Paxlovid, hit $29.267 billion. Fast-forward to 2023, and with COVID largely behind us, revenue from those products plummeted, pushing cash flow from operations down to $8.7 billion.
With that in mind, it's not difficult to understand why the stock fell by roughly 23% over the last year....
Read the full article on Seeking Alpha
For further details see:
Pfizer: Buy This Big Yielder On The Strong Pipeline